Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
65%
Nonalcoholic Steatohepatitis
57%
PEGylated
46%
Fibroblast Growth Factor 21 (FGF21)
46%
PD0325901
46%
Triglyceride Biosynthesis
46%
Hepatic Energy Metabolism
46%
Novel Regulator
46%
Pegbelfermin
46%
Fibroblast Growth Factor 1 (FGF1)
34%
Metabolic Syndrome
34%
Cirrhosis
24%
TMX1
20%
Approved Drugs
18%
Hepatic Steatosis
18%
Liver Disease
13%
Hepatic Manifestations
11%
Hepatocellular Carcinoma
11%
Downstream Targets
11%
Functional Mechanism
11%
Adult Population
11%
Cardiovascular Disease
11%
Disease Spectrum
11%
Pathophysiology
11%
Hepatic Lipid
11%
Disease Stage
11%
Metabolism Function
11%
Molecular Mechanism
11%
Hepatic Function
11%
Global Epidemic
11%
Simple Steatosis
11%
Lipid-lowering
11%
European Medicines Agency
11%
Mouse Model
11%
In Vitro System
11%
Leading Causes of Death
11%
Hepatic Lipid Metabolism
11%
Biological Function
11%
Metabolic Effects
11%
Individual Role
11%
Fibroblast Growth Factor Receptor Signaling
7%
Pleiotropic Effects
6%
Clinical Trials
6%
Long-term Safety
6%
Obesity Resistance
6%
Area Cover
6%
Liver Histology
6%
Systemic Treatment
6%
Safety Issues
6%
Insulin Resistance
6%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Fibroblast Growth Factor 21
92%
Drug Delivery System
46%
Bile Acid
46%
Fibroblast Growth Factor 19
46%
Clinical Trial
27%
Metabolic Syndrome X
27%
Disease
23%
N (2,3 Dihydroxypropoxy) 3,4 Difluoro 2 (2 Fluoro 4 Iodoanilino)benzamide
23%
Adverse Event
19%
Fibroblast Growth Factor
18%
Liver Cirrhosis
18%
Cardiovascular Disease
16%
Malignant Neoplasm
15%
Fibroblast Growth Factor Receptor
15%
Hepatotoxicity
15%
Fatty Liver
13%
Steatosis
9%
Mouse Model
9%
Epidemic
9%
Liver Cell Carcinoma
9%
Prevalence
9%
Fibroblast Growth Factor 1
9%
Liver Disease
9%
Pathophysiology
9%
Mitogen Activated Protein Kinase Kinase Inhibitor
7%
Biological Marker
7%
C57BL 6 Mouse
7%
Gastrointestinal Symptom
7%
Metabolic Disorder
7%
Preclinical Study
7%
Disease Activity
7%
Transcriptome
7%
Mouse
7%
Neoplasm
7%
Non Insulin Dependent Diabetes Mellitus
7%
Biochemistry, Genetics and Molecular Biology
Homeostasis
50%
Polypeptide N-Acetylgalactosaminyltransferase
46%
Bile Acid
46%
Triglyceride
46%
Glycosylation
46%
GALNT2
46%
Anabolism
46%
Bile Acid Metabolism
46%
Mouse
29%
MAPK Signaling
23%
Signal Transduction
23%
Enzyme
16%
Acyltransferase
13%
N-Acetyltransferase
13%
Bile Composition
11%
MEK Inhibitor
11%
Treatment Interruption
11%
Hepatocyte
11%
C57BL 6 Mouse
11%
Small Molecule
11%
Transcriptional Repressor
11%
Gene Expression Profiling
11%
Mitogen-Activated Protein Kinase
11%
Drug Dose Reduction
11%
Posttranslational Modification
9%
Insulin Receptor
9%
High-Density Lipoprotein
9%
Diacylglycerol
9%
Blood Lipids
9%
Lipoprotein Metabolism
9%